Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,454 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood draw for the study participants Clear all
Completed Not applicable Interventional

Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications

NCT05166382
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Diseases
Interventions
Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D), Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 7, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

NCT01246960
View directory record Official record
Conditions
Stomach Cancer, Esophageal Cancer
Interventions
Ramucirumab, Placebo, Oxaliplatin, Leucovorin, 5-Fluorouracil
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
58
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Alhambra, California + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 7, 2026, 4:10 AM EDT
Active, not recruiting Phase 2 Interventional

Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

NCT05621759
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Cyclophosphamide, Abatacept, Tacrolimus
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 7, 2026, 4:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The UnProcessed Pantry Project (UP3)

NCT04241133
View directory record Official record
Conditions
Diet, Healthy, Diet Habit, Disease, Chronic, Health Behavior, Rural Health
Interventions
The UnProcessed Pantry Project (UP3)
Behavioral
Lead sponsor
Montana State University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 7, 2026, 4:10 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
18
States / cities
Augusta, Georgia • Chicago, Illinois • Boston, Massachusetts + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 7, 2026, 4:10 AM EDT
Recruiting Phase 2 Interventional

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

NCT07447076
View directory record Official record
Conditions
Recurrent Atypical Teratoid/Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS
Interventions
Lumber Puncture, Blood Specimen Collection, Magnetic resonance imaging (MRI), Gemcitabine, Paxalisib, Tumor Biopsy
Procedure · Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
1 Year to 39 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 7, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

Preventing Acute Chest Syndrome by Transfusion Feasibility Study

NCT00951808
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Single blood transfusion, Standard care
Biological · Behavioral
Lead sponsor
Carelon Research
Other
Eligibility
2 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 7, 2026, 4:10 AM EDT
Recruiting Not applicable Interventional

ACL Reconstruction Rehabilitation With Exercise and Psychological Support

NCT06991192
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction Rehabilitation
Interventions
Rehabilitation with Exercise and Psychological Support (REPS)
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
15 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 7, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

NCT05103332
View directory record Official record
Conditions
Hypertension
Interventions
Indapamide, Amlodipine, Olmesartan, Placebo, Zilebesiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
74
States / cities
Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 7, 2026, 4:10 AM EDT
Completed No phase listed Observational

Study to Explore Natural Daily Variation and Impact of Stress in HIV Levels

NCT02895087
View directory record Official record
Conditions
HIV
Interventions
Diurnal Variation Group, External Stress Group
Other
Lead sponsor
University of Melbourne
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
San Francisco, California • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 7, 2026, 4:10 AM EDT
Active, not recruiting Phase 2 Interventional

Enhancing Week-long Psychological Treatment for PTSD With Ketamine

NCT05737693
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 7, 2026, 4:10 AM EDT
Completed Not applicable Interventional

The Healthy Eating and Active Living to Reverse Diabetes Pilot Study

NCT07316569
View directory record Official record
Conditions
Diabete Type 2, Diabetes, Overweight , Obesity
Interventions
Intensive Multicomponent Healthy Eating and Weight Loss Intervention, Enhanced Usual Diabetes Care
Behavioral
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 7, 2026, 4:10 AM EDT
Completed Not applicable Interventional

Blood Flow Restriction and Exercise in Parkinson's Disease

NCT07221994
View directory record Official record
Conditions
Parkinson' Disease
Interventions
Blood flow restriction (BFR) and aerobic exercise via recumbent stepping (Nu-Step)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 7, 2026, 4:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity

NCT06638671
View directory record Official record
Conditions
Exercise Capacity, Metformin
Interventions
Metformin Hydrochloride, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 7, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

NCT01281306
View directory record Official record
Conditions
Systolic Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 7, 2026, 4:10 AM EDT
Completed Not applicable Interventional

Connected Health Care in Exercise Program for Obesity

NCT03446235
View directory record Official record
Conditions
Obesity, Physical Activity, Exercise
Interventions
Exercise instruction with motivational interview, Self-monitoring
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 59 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 7, 2026, 4:10 AM EDT
Not listed Not applicable Interventional

Improving Diabetes Equity and Advancing Care Study

NCT06040463
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support
Behavioral
Lead sponsor
Sinai Health System
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 7, 2026, 4:10 AM EDT
Completed Not applicable Interventional

I Can Do This! Managing My Diabetes

NCT06695533
View directory record Official record
Conditions
Diabetes
Interventions
Diabetes self management workbook
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 7, 2026, 4:10 AM EDT
Completed No phase listed Observational Results available

In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.

NCT00788255
View directory record Official record
Conditions
Anesthesia
Interventions
Final exogenous oxytocin concentration=22.5 μU/mL, Final exogenous oxytocin concentration=30.1μU/mL, Final exogenous oxytocin concentration=32.9μU/mL
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 7, 2026, 4:10 AM EDT
Terminated No phase listed Observational

Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab

NCT04791215
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Observational
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 7, 2026, 4:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Role of Flavanols in Exercise and Aging

NCT01557738
View directory record Official record
Conditions
Aging
Interventions
High Flavanol Trial, Low Flavanol Trial, High Flavanol Trial; long-term, Low Flavanol Trial; long-term effects
Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 7, 2026, 4:10 AM EDT
Completed Phase 1 Interventional

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

NCT03544125
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Durvalumab, Olaparib
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 7, 2026, 4:10 AM EDT
Active, not recruiting Phase 3 Interventional

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

NCT05669755
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years and older
Enrollment
7,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
119
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 7, 2026, 4:10 AM EDT
Completed No phase listed Observational Results available

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01613599
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 7, 2026, 4:10 AM EDT